Photo: Thomas Brun / NTB ScanPix

PCI Biotech works with Astra Zeneca

Bjellesermoni Oslo Børs PCI Biotech

PCI Biotech reveals they have been collaborating with Astra Zeneca since 2015.

Our member PCI Biotech grabbed the opportunity during their third quarter report this week to announce who their mystery collaboration partner since 2015 has been. The “top-ten pharma company in the world”, who has been helping them, is Astra Zeneca.

PCI Biotech is a company that is based on a technology called photochemical internalisation, which was invented by Professor Kristian Berg from the Norwegian Radium Hospital. The technology is a kind of drug and gene delivery method. It aims to improve the release of big molecules and chemotherapy drugs to the targeted cancer cells. The technology can also potentially be used for a wide variety of diseases and treatments.

The company currently develops three different programs:

  1. FimaCHEM: enhancing the effect of chemotherapy drugs for localised treatment of cancer
  2. FimaVACC: delivering cancer vaccines effectively to the cancer cell and kick-starting a immune response
  3. fimaNAc: delivering nucleid acid therapeutics

You can read more about the revolutionary light technology in the following article:

Astra Zeneca has said that the results from their tests of fimaNAc look very promising in the oncology area. Now, they wish to see if the same technology can work in other disease areas. The pre-clinical collaboration agreement between PCI Biotech and Astra Zeneca lasts until the end of 2019 and the following 6 months will be used to evaluate the potential for further collaboration.

Per Walday, CEO of PCI Biotech, had the following to say about the collaboration:

“Ensuring sufficient intracellular delivery of nucleic acid therapeutics is a major hurdle to realise the vast therapeutic potential of this drug class. We believe that the fimaNAc technology can play an important part in solving this delivery challenge.  PCI Biotech’s current collaborations and their progress suggest that external partners share this view.”

Listen to Per Walday and Ronny Skuggedal talk more about PCI Biotech, the “light technology”, their third quarter report and future milestones in the podcast Radium episode 103.

Sign up to Oslo Cancer Cluster newsletter!

Reports from the third quarter from our members have been published. Photo: Unsplash

What’s new in Q3?

Two persons working in front a two laptops.

Positive results from clinical trials, revenue growth and new clinical collaborations … Read some of the third quarter developments from our members below.

BerGenBio logo

BerGenBio

  • BerGenBio showed results from their clinical trial for patients with non-small cell lung cancer, who have previously been treated with chemotherapy. The results showed they met primary and secondary endpoints.
  • The company presented interim safety data from a Phase Ib/II trial. They are testing their drug bemcentinib in combination with pembrolizumab on melanoma patients. The data shows the combination is well tolerated by patients.
  • The U.S. Food and Drug Administration (FDA) has granted bemcentinib Fast Track Designation. This means they will do an expedited review of the investigational drug. The designation is for the treatment of elderly patients with acute myeloid leukemia (AML), who have relapsed.

Read more in the press release from BerGenBio

Nordic Nanovector logo

Nordic Nanovector

  • Nordic Nanovector raised approximately NOK 243 million in private placement of new shares. This will provide further funds to continue the clinical development of their drug Betalutin, manufacturing and other commercial activities.
  • The company presented new results from a clinical trial, testing their drug Betalutin on patients with non-Hodgkins lymphoma (a type of blood cancer). The median duration of response was 13.6 months for all responders and 32.0 months for complete responders.
  • The company reported 3 out of 3 patient responses in the first patient cohort in one of their clinical trials. The patients were given Betalutin in combination with rituximab to treat 3rd-line relapsed or refractory follicular lymphoma (also a type of blood cancer).

Read more in the press release from Nordic Nanovector

Photocure logo

Photocure

  • Photocure reported a revenue growth of 42% in local currency for the US market.
  • The revenues in the Nordics declined 7% to NOK 9.9 million (NOK 10.6 million) in the third quarter.
  • The company entered into a licensing agreement with Asieris Meditech Co. to commercialize the product Cevira to the global market. Cevira is a non-invasive photodynamic therapy for HPV-related (cervical) diseases.

Read more in the press release from Photocure

 

Targovax logo

Targovax

  • Targovax presented new data from the first part of the clinical trial of their oncolytic virus. The trial has shown clinical responses in three out of nine patients. This treatment targets patients with refractory advanced melanoma (skin cancer).
  • The company announced an expansion of the clinical trial of the oncolytic virus ONCOS-102 in combination with the checkpoint inhibitor Imfinzi. This trial is open for patients with advanced peritoneal malignancies (a rare cancer that develops in the tissue that lines the abdomen).
  • The company publicised that Oslo University Hospital will become a site for the clinical trial of their oncolytic virus ONCOS-102.

Read more in the press release from Targovax

 

Ultimovacs logo

Ultimovacs

  • Ultimovacs presented long-term results from the clinical study of their therapeutic cancer vaccine UV1. The patients have non-small cell lung cancer and the trial has shown a 4-year overall survival rate of 39% (7 of 18 patients are still alive).
  • New data from their prostate cancer trial showed a 5-year overall survival rate of 50% (11 of 22 patients are still alive).
  • A phase II clinical trial for patients with malignant melanoma (skin cancer) is projected to start in the first quarter of 2020.

Read more in the press release from Ultimovacs

 

More third quarter reports from our other members are or will be made available on their respective websites.

 

Jónas Einarsson, CEO of Radforsk, and Elisabeth Kirkeng Andersen, Communications Manager at Radforsk, invite guests on the podcast Radium to discuss recent developments in the Norwegian oncology field.

100 episodes of cancer research & development

Jonas Einarsson and Elisabeth Kirkeng Andersen, from RADFORSK, are the two people behind the podcast Radium.

From a relatively modest podcast to packed live shows at Arendalsuka, Radium has in three years grown into a leading cancer podcast in Norway.

Radium is a weekly podcast about Norwegian cutting-edge cancer research and development, produced by the evergreen investment fund Radforsk. Radforsk has 15 companies in its portfolio, of which five are on the stock market and 10 are also members of Oslo Cancer Cluster. Elisabeth Kirkeng Andersen, Communications Manager, and Jónas Einarsson, CEO of Radforsk, bring guests on the show to discuss recent development in the oncology field and news from the portfolio companies.

“Three years ago, Elisabeth came to me and said ‘Now, we are going to do something new – we will make a podcast’. I replied ‘That’s great! But what is a podcast?’” Einarsson said.

Andersen then took the first steps and employed students from the media program at Ullern Upper Secondary School to help with sound production.

 

Interested investors

Andersen and Einarsson quickly noticed there is great interest in the podcast, especially from investors and shareholders. They want to stay updated about Norwegian cancer research, a relatively new but growing sector. They often send in questions, which Andersen and Einarsson ask the guests in the studio.

“We try to simplify things. It is easier to hear it explained by someone from a company, than to read a difficult press release,” Andersen said.

“I think the best episodes are when we get a good dialogue with the CEOs of the companies, especially when things get a little heated. I try to lure them out on the thin ice to make them tell us more,” Einarsson said.

The popular podcast format has exploded in recent years, giving people access to accessible conversations that they can listen to whenever they want.

“There is no strict direction. We say that we are just going to have a conversation and then we talk for an hour or more,“ Einarsson said. “We have a down-to-earth style, but Elisabeth will pull us back if the guests or I dive too deep into details.”

 

Affecting health policies

Radium has also had several events with live streaming. At Arendalsuka this year, the premises were fully packed with eager listeners at both of their live shows.

“At Arendal, we try to have podcasts with others in the cancer field and aim to be more political. We think it has worked very well, because we can reach out to even more people when we stream the event,” Elisabeth said.

“I think the podcast will interest people working in the health industry and health politics too,” Einarsson said. “For example, the health minister was a guest for an entire hour, talking about current challenges.”

 

Best of Norwegian research

Radium regularly invites famous names from the Norwegian research community too. Steinar Aamdal, a prominent researcher in cancer immunotherapies has been a guest. Another cancer expert, Håvard Danielsen, who works on the DoMore project at Oslo University Hospital, has also talked on the podcast.

Øyvind Bruland and Roy Larsen, the serial entrepreneurs who started Algeta, Nordic Nanovector and OncoInvent, also visited the show.

Soon, Radium will host Kristian Berg, the researcher behind PCI Biotech’s technology: photochemical internalisation technology.

“I believe people think it is very interesting to, through the podcast, meet the people who actually have researched and developed the treatments,” Einarsson said.

 

For the patients

Einarsson and Andersen have also noticed that cancer patients or their family members listen to the podcast to hear about what is happening in the field.

“It is important to communicate that we do this for the patients. An important driving force is that we wish to contribute to developing better treatments for patients,” said Andersen.

“Every time the survival rate increases, it means one patient gets to live longer – and perhaps that is because of a treatment we have helped to develop,” said Einarsson. “To be a part of the journey with immunotherapy over the last 20 years, for an old doctor like me, is absolutely fantastic.”

 

Listen and download Radium:

 

Send in your ideas for guests and topics directly to Radium.

 

Episode 100 was recorded at Kulturhuset in Oslo, with several interesting guests, a friendly atmosphere and, delicious food and beverages. Stay tuned for upcoming live events via Radforsk’s Facebook page!

 

Sign up to OCC monthly newsletter

Torbjørn Furuseth, Chief Financial Officer, Targovax, is delighted to announce that the company's second part of the clinical trial for skin cancer patients will be held at Oslo University Hospital.

New clinical trial at Oslo University Hospital

Torbjörn Furuseth, Targovax

Our member Targovax has announced a new clinical trial for skin cancer patients at Oslo University Hospital.

The second part of a clinical trial for patients with refractory advanced melanoma (a type of skin cancer) will take place at Oslo University Hospital.

“We are excited that we can offer this treatment alternative to patients in our home country, and hopefully it will help us to recruit more patients faster,” said Torbjørn Furuseth, Chief Financial Officer, Targovax.

Targovax is a Norwegian biotech company that develops oncolytic viruses called ONCOS-102 to destroy cancer cells. The treatment is targeted towards solid tumours that are especially hard to treat. The ultimate goal is to activate the patient’s immune system to fight cancer.

Promising results

“The trial is until now conducted at three top hospitals in the US, where competition for patients to clinical trials is high. Oslo University Hospital is also a great cancer center, and currently there are no trials offered to this patient population,” said Furuseth.

Three out of nine patients responded to the treatment during the first part of the clinical trial. This included one complete response and two partial responses.

Dr. Magnus Jäderberg, CMO of Targovax, said: “It is promising to see this level of clinical responses after only three ONCOS-102 injections, including a complete response, which is rare in this heavily pre-treated patient population.”

A forceful combination

The treatment involves a combination of an oncolytic virus and an anti-PD1 checkpoint inhibitor.

The oncolytic virus is a modified virus that has been developed to selectively attack and kill cancer cells. You can read more about the oncolytic viruses on Targovax’s official website.

The anti-PD1 checkpoint inhibitor disrupts the interaction between proteins on the surface of cancer cells. This stops the cancer from evading the immune system.

“Earlier this year, we decided to expand the trial to test a more intensified schedule of ONCOS-102, and it will be interesting to see whether this regimen can generate more and deeper clinical responses,” said Dr. Alexander Shoushtari, Principal Investigator, Memorial Sloan Kettering Cancer Centre, New York.

The second part of the clinical trial is currently enrolling new patients.

 

Sign up to OCC newsletter